Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The early relapse of ovarian cancer occurring within 6 months of chemotherapy including
platinum regimen are called relapses 'platinum resistant' consecutively patients die quickly
of their disease. For relapses occurring between 6 and 12 months, no recommendation occur and
few studies are conducted. Therefore it seems interesting to develop a research on intensive
chemotherapy using a combination of carboplatin (a drug widely used in most ovarian cancer)
with Topotecan , use in a high dose protocol. Topotecan has demonstrated its efficacy in
relapse ovarian cancer and its possible use in high doses, a recent study (ITOV01) have
demonstrated the feasibility of dose escalation of topotecan monotherapy (MTD set at 9 mg /
m² / dx 5 days). This project is a feasibility research of the combination of topotecan and
carboplatin in a high dose escalation protocol for early ovarian cancer relapse occurring 6
to 12 months after conventional chemotherapy-based platinum salts.